Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3459359 | 0.81 | CA1 (0.70) | HPGDCYP1A2MAPTALDH1A1TP53 | |
| SCHEMBL7978017 | 0.81 | HPGD (0.68) | HPGDCYP1A2MAPTALDH1A1TP53 | |
| SCHEMBL5885064 | 0.81 | HPGD (0.68) | HPGDCYP1A2MAPTALDH1A1TP53 | |
| SCHEMBL1561753 | 0.79 | HPGD (0.66) | HPGDCYP1A2MAPTALDH1A1TP53 | |
| SCHEMBL9539900 | 0.79 | ALDH1A1 (0.81) | HPGDCYP1A2MAPTALDH1A1TP53 | |
| SCHEMBL461826 | 0.79 | HPGD (0.66) | HPGDCYP1A2MAPTALDH1A1TP53 | |
| SCHEMBL16634735 | 0.79 | HPGD (0.66) | HPGDCYP1A2MAPTALDH1A1TP53 | |
| SCHEMBL7870127 | 0.79 | HPGD (0.66) | HPGDCYP1A2MAPTALDH1A1TP53 | |
| SCHEMBL727376 | 0.78 | ALDH1A1 (0.64) | HPGDCYP1A2MAPTALDH1A1TP53 | |
| SCHEMBL28618627 | 0.78 | HPGD (0.64) | HPGDCYP1A2MAPTALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053236-B2 | Substituted isoselenazolone anti-infective, anti-inflammatory, anti-cancer, cytoprotective, neuroprotective, and anti-oxidant agents | THE UNIVERSITY OF TOLEDO (US) | 2021-07-06 | — | — | US | disclosed |
| US-20190161482-A1 | SUBSTITUTED ISOSELENAZOLONE ANTI-INFECTIVE, ANTI-INFLAMMATORY, ANTI-CANCER, CYTOPROTECTIVE, NEUROPROTECTIVE, AND ANTI-OXIDANT AGENTS | THE UNIVERSITY OF TOLEDO (US) | 2019-05-30 | — | — | US | disclosed |
| WO-2017223160-A1 | SUBSTITUTED ISOSELENAZOLONE ANTI-INFLAMMATORY, ANTI-CANCER, CYTOPROTECTIVE, NEUROPROTECTIVE, AND ANTI-OXIDANT AGENTS | THE UNIVERSITY OF TOLEDO (US) | 2017-12-28 | — | — | WO | disclosed |
| EP-1562640-B1 | METHODS FOR PURIFYING RADIOLABELLED COMPOUNDS | UNIV MCMASTER (CA) | 2012-12-05 | — | — | EP | disclosed |
| US-8034939-B2 | 1-{3-H-imidazo[4,5-c]pyridin-2-yl}-3,4-dihydro-2H-pyrido[2,1-a] isoindole-6-one; anticarcinogenic agent: solid tumor and leukemia; neurodegenerative diseases: Alzheimer's and Huntington's diseases | AVENTIS PHARMA S.A.. (FR) | 2011-10-11 | — | — | US | disclosed |
| EP-1869042-B1 | NOVEL ISOINDOLE DERIVATIVES, COMPOSITIONS CONTAINING SAME, PREPARATION THEREOF AND PHARMACEUTICAL USES THEREOF IN PARTICULAR AS INHIBITORS OF CHAPERONE PROTEIN HSP90 ACTIVITIES | AVENTIS PHARMA SA (FR) | 2011-02-02 | — | — | EP | disclosed |
| US-20090005545-A1 | METHODS FOR PURIFYING RADIOLABELLED COMPOUNDS | MCMASTER UNIVERSITY | 2009-01-01 | — | — | US | disclosed |
| US-20080119507-A1 | Novel Isoindole Derivatives, Compositions Containing Same, Preparation Thereof and Pharmaceutical Uses Thereof in Particular as Inhibitors of Chaperone Protein HSP90 Activities | AVENTIS PHARMA S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| US-7335347-B2 | Methods for purifying radiolabelled compounds | MCMASTER UNIVERSITY (CA) | 2008-02-26 | — | — | US | disclosed |
| US-7323474-B2 | Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase | NOVARTIS AG (CH) | 2008-01-29 | — | — | US | disclosed |
| EP-1562640-A2 | METHODS FOR PURIFYING RADIOLABELLED COMPOUNDS | Molecular Insight Pharmaceuticals, Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1254138-B1 | PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE | NOVARTIS AG (CH) | 2005-05-11 | — | — | EP | disclosed |
| US-20040260073-A1 | Methods for purifying radiolabelled compounds | MCMASTER UNIVERSITY (CA) | 2004-12-23 | — | — | US | disclosed |
| US-20040209894-A1 | Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase | BOLD GUIDO | 2004-10-21 | — | — | US | disclosed |
| WO-2004035744-A2 | METHODS FOR PURIFYING RADIOLABELLED COMPOUNDS | BIOSTREAM, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| US-6706731-B2 | WITH ISOQUINOLINE DERIVATIVES AS ANTITUMOR AGENTS | NOVARTIS AG (CH) | 2004-03-16 | — | — | US | disclosed |
| US-20030158409-A1 | Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase | NOVARTIS AG (CH) | 2003-08-21 | — | — | US | disclosed |
| EP-1254138-A1 | PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE | Novartis AG (CH) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001058899-A1 | PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE | NOVARTIS AG (CH) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11053236-B2 | Substituted isoselenazolone anti-infective, anti-inflammatory, anti-cancer, cytoprotective, neuroprotective, and anti-oxidant agents | AIFM1, HSPE1, COX15 | HPGD 212/4885CYP1A2 3257/4885MAPT 1171/4885 |
| US-20190161482-A1 | SUBSTITUTED ISOSELENAZOLONE ANTI-INFECTIVE, ANTI-INFLAMMATORY, ANTI-CANCER, CYTOPROTECTIVE, NEUROPROTECTIVE, AND ANTI-OXIDANT AGENTS | AIFM1, HSPE1, COX15 | HPGD 212/4885CYP1A2 3257/4885MAPT 1171/4885 |
| US-20040209894-A1 | Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase | FLT1, FLT4, KDR | HPGD 410/4885CYP1A2 269/4885MAPT 2394/4885 |
| US-20080119507-A1 | Novel Isoindole Derivatives, Compositions Containing Same, Preparation Thereof and Pharmaceutical Uses Thereof in Particular as Inhibitors of Chaperone Protein HSP90 Activities | HSP90B1, HSP90AB2P, HSP90AB1 | HPGD 432/4885CYP1A2 896/4885MAPT 767/4885 |
| US-20030158409-A1 | Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase | FLT1, FLT4, KDR | HPGD 336/4885CYP1A2 374/4885MAPT 1907/4885 |
| US-20040260073-A1 | Methods for purifying radiolabelled compounds | PAICS, PFAS, NPEPPS | HPGD 3863/4885CYP1A2 2505/4885MAPT 2835/4885 |
| US-20090005545-A1 | METHODS FOR PURIFYING RADIOLABELLED COMPOUNDS | PAICS, PFAS, NPEPPS | HPGD 3863/4885CYP1A2 2505/4885MAPT 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.